Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML

 

- CR rate of 36% in Intent to Treat or ITT (n=11) subjects with durability - CR rate of 44% in subjects treated with Annamycin (n=9) - Durability of CR's up to 8 months & climbing (no relapses to date) - Recruitment in MB-106 Phase 1B/2 clinical trial reaches 59% - Announces Publication for 65th ASH Annual Meeting and Exposition - Annamycin continues to be 100% non-cardiotoxic https://www.biospace.com/article/releases/moleculin-presents-positive-interim-data-from-phase-1b-2-clinical-trial-in-aml-at-meeting-with-kol-s-in-conjunction-with-ash-annual-meeting/